Data on the Safety of Psoriasis Therapies

Highlights of Skin Disease Education Foundation’s 38th Annual Hawaii Dermatology Seminar

Data on the Safety of Psoriasis Therapies

Jun
2014
Vol. 33. No. 4
Craig L. Leonardi, MD

Safety remains paramount to the clinical utility of a therapy. Evaluation of safety is an ongoing process that does not end when a therapy becomes commercially available. This article reviews recent data pertaining to the safety profile of two therapeutic classes widely used in the treatment of psoriasis: inhibitors of tumor necrosis factor-α and agents that target interleukin-12/23.

VIEW FULL ARTICLE PDF